Pfizer Begin Period Cash Flow from 2010 to 2024
| PFE Stock | USD 25.57 0.53 2.03% |
Begin Period Cash Flow | First Reported 1990-03-31 | Previous Quarter 719 M | Current Value 1.1 B | Quarterly Volatility 1.2 B |
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 B, Interest Expense of 2.3 B or Total Revenue of 39.5 B, as well as many indicators such as Price To Sales Ratio of 4.61, Dividend Yield of 0.0598 or PTB Ratio of 1.73. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
Pfizer | Begin Period Cash Flow |
Latest Pfizer's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Pfizer Inc over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Pfizer's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Pfizer Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 2,410,213,333 | |
| Geometric Mean | 1,753,564,754 | |
| Coefficient Of Variation | 97.34 | |
| Mean Deviation | 1,438,791,111 | |
| Median | 1,825,000,000 | |
| Standard Deviation | 2,345,997,778 | |
| Sample Variance | 5503705.6T | |
| Range | 9.6B | |
| R-Value | (0.39) | |
| Mean Square Error | 5030722.9T | |
| R-Squared | 0.15 | |
| Significance | 0.15 | |
| Slope | (204,000,000) | |
| Total Sum of Squares | 77051878T |
Pfizer Begin Period Cash Flow History
About Pfizer Financial Statements
Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 468 M | 444.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out the analysis of Pfizer Correlation against competitors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.67 | Earnings Share 0.75 | Revenue Per Share 10.493 | Quarterly Revenue Growth 0.312 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.